Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Ratio (2018 - 2025)

Cyclerion Therapeutics has reported Equity Ratio over the past 8 years, most recently at 0.91 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 1.56% year-over-year to 0.91; the TTM value through Dec 2025 reached 0.91, down 1.56%, while the annual FY2025 figure was 0.91, 1.56% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.91 at Cyclerion Therapeutics, down from 0.92 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.92 in Q4 2024 and troughed at 0.34 in Q1 2023.
  • A 5-year average of 0.78 and a median of 0.85 in 2023 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: tumbled 56.96% in 2023 and later soared 154.86% in 2024.
  • Year by year, Equity Ratio stood at 0.81 in 2021, then fell by 28.9% to 0.58 in 2022, then soared by 45.99% to 0.84 in 2023, then rose by 9.51% to 0.92 in 2024, then dropped by 1.56% to 0.91 in 2025.
  • Business Quant data shows Equity Ratio for CYCN at 0.91 in Q4 2025, 0.92 in Q3 2025, and 0.91 in Q2 2025.